Please assess the completion status of the following clinical trial:

Trial Title: Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18 years and older) with clinically significant macular edema (CSME) with visual acuity less than 20/60 to Hand motion in the study eye.~* Patients should have persistent CSME three months after laser therapy or three months after intraocular injection of Avastin or triamcinolone. These interventions could be multiple or combined.~* Optical coherence tomography (OCT) scan demonstrating more than 275 microns retinal thickness in central subfield of study eye.~* Ability to understand study instructions, interventions and potential complications.~* History of reasonably controlled Diabetes mellitus (DM), ≤ 8.5HbA1c that has been evaluated in the last 3 months.~* Ability to undergo contraceptive protection during and 3 months after intraocular injections.~* Clear demonstration (in female patients) of commitment to avoid pregnancy and a negative urine pregnancy test at baseline for women of childbearing potential.~* Clear understanding of teratogenic potential of MTX.~Exclusion Criteria:~* History of allergy to MTX.~* An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition.~* An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, epiretinal membrane, etc.).~* An eye treated for Glaucoma~* Eyes that underwent vitrectomy~* History of intraocular malignancies.~* Intraocular surgery with the prior 3 months.~* Recent significant change in diabetic medications.~* Insulin usage less than a year.~* Life threatening co morbidities such as cancer under therapy.~* Use of oral, intravenous, periocular or intraocular corticosteroids (steroids) in prior 3 months.~* Liver function that exceeds three times the upper limit of normal at baseline, or within 6 weeks of that appointment.~* Pregnant females.~* Vitreous hemorrhage (active) in study eye~* Anticipation of the need for laser pan retinal photocoagulation in the next 6 months.~* Media opacities~* Herpetic disease of cornea~* Corneal dystrophy with significant corneal edema.~* Any major surgery within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Methotrexate 25mg/ml (Type: OTHER): Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.

Based on this trial design, predict the completion outcome and termination type (if applicable).